title: The SCIentinel study--prospective multicenter study to define the spinal cord injury-induced immune depression syndrome (SCI-IDS)--study protocol and interim feasibility data.
abstract: BACKGROUND
  Infections are the leading cause of death in the acute phase following spinal cord injury and qualify as independent risk factor for poor neurological outcome ("disease modifying factor"). The enhanced susceptibility for infections is not stringently explained by the increased risk of aspiration in tetraplegic patients, neurogenic bladder dysfunction, or by high-dose methylprednisolone treatment. Experimental and clinical pilot data suggest that spinal cord injury disrupts the balanced interplay between the central nervous system and the immune system. The primary hypothesis is that the Spinal Cord Injury-induced Immune Depression Syndrome (SCI-IDS) is 'neurogenic' including deactivation of adaptive and innate immunity with decreased HLA-DR expression on monocytes as a key surrogate parameter. Secondary hypotheses are that the Immune Depression Syndrome is i) injury level- and ii) severity-dependent, iii) triggers transient lymphopenia, and iv) causes qualitative functional leukocyte deficits, which may endure the post-acute phase after spinal cord injury.
  
  
  METHODS
  SCIentinel is a prospective, international, multicenter study aiming to recruit about 118 patients with acute spinal cord injury or control patients with acute vertebral fracture without neurological deficits scheduled for spinal surgery. The assessment points are: i) <31 hours, ii) 31-55 hours, iii) 7 days, iv) 14 days, and v) 10 weeks post-trauma. Assessment includes infections, concomitant injury, medication and neurological classification using American Spinal Injury Association impairment scale (AIS) and neurological level. Laboratory analyses comprise haematological profiling, immunophenotyping, including HLA-DR expression on monocytes, cytokines and gene expression of immune modulators. We provide an administrative interim analysis of the recruitment schedule of the trial.
  
  
  CONCLUSIONS
  The objectives are to characterize the dysfunction of the innate and adaptive immune system after spinal cord injury and to explore its proposed 'neurogenic' origin by analyzing its correlation with lesion height and severity. The trial protocol considers difficulties of enrolment in an acute setting, and loss to follow up. The administrative interim analysis confirmed the feasibility of the protocol. Better understanding of the SCI-IDS is crucial to reduce co-morbidities and thereby to attenuate the impact of disease modifying factors to protect neurological "outcome at risk". This putatively results in improved spinal cord injury medical care.
  DRKS00000122 (German Clinical Trials Registry).
authors.forename: Marcel A
authors.initials: MA
authors.lastname: Kopp
authors.forename: Claudia
authors.initials: C
authors.lastname: Druschel
authors.forename: Christian
authors.initials: C
authors.lastname: Meisel
authors.forename: Thomas
authors.initials: T
authors.lastname: Liebscher
authors.forename: Erik
authors.initials: E
authors.lastname: Prilipp
authors.forename: Ralf
authors.initials: R
authors.lastname: Watzlawick
authors.forename: Paolo
authors.initials: P
authors.lastname: Cinelli
authors.forename: Andreas
authors.initials: A
authors.lastname: Niedeggen
authors.forename: Klaus-Dieter
authors.initials: KD
authors.lastname: Schaser
authors.forename: Guido A
authors.initials: GA
authors.lastname: Wanner
authors.forename: Armin
authors.initials: A
authors.lastname: Curt
authors.forename: Gertraut
authors.initials: G
authors.lastname: Lindemann
authors.forename: Natalia
authors.initials: N
authors.lastname: Nugaeva
authors.forename: Michael G
authors.initials: MG
authors.lastname: Fehlings
authors.forename: Peter
authors.initials: P
authors.lastname: Vajkoczy
authors.forename: Mario
authors.initials: M
authors.lastname: Cabraja
authors.forename: Julius
authors.initials: J
authors.lastname: Dengler
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Ertel
authors.forename: Axel
authors.initials: A
authors.lastname: Ekkernkamp
authors.forename: Peter
authors.initials: P
authors.lastname: Martus
authors.forename: Hans-Dieter
authors.initials: HD
authors.lastname: Volk
authors.forename: Nadine
authors.initials: N
authors.lastname: Unterwalder
authors.forename: Uwe
authors.initials: U
authors.lastname: Kölsch
authors.forename: Benedikt
authors.initials: B
authors.lastname: Brommer
authors.forename: Rick C
authors.initials: RC
authors.lastname: Hellmann
authors.forename: Ramin R Ossami
authors.initials: RR
authors.lastname: Saidy
authors.forename: Ines
authors.initials: I
authors.lastname: Laginha
authors.forename: Harald
authors.initials: H
authors.lastname: Prüss
authors.forename: Vieri
authors.initials: V
authors.lastname: Failli
authors.forename: Ulrich
authors.initials: U
authors.lastname: Dirnagl
authors.affiliation: Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. jan.schwab@charite.de.
authors.forename: Jan M
authors.initials: JM
authors.lastname: Schwab
mesh_terms: D020274:Autoimmune Diseases of the Nervous System / Q000175:diagnosis* / Q000453:epidemiology*; D016208:Databases, Factual; D005240:Feasibility Studies; D006801:Humans; D038622:Internationality; D008137:Longitudinal Studies; D011446:Prospective Studies; D013119:Spinal Cord Injuries / Q000175:diagnosis* / Q000453:epidemiology*